As compared to fluorouracil, doxorubicin, and cyclophosphamide, an adjuvant taxane-based regimen containing docetaxel, doxorubicin, and cyclophosphamide was shown to increase the rate of disease-free survival by 32% among women with high-risk, node-negative breast cancer.
As compared to fluorouracil, doxorubicin, and cyclophosphamide (FAC), an adjuvant taxane-based regimen containing docetaxel, doxorubicin, and cyclophosphamide (TAC) was shown to increase the rate of disease-free survival by 32% among women with high-risk, node-negative breast cancer. The benefit of TAC was consistent, regardless of hormone-receptor status, menopausal status, or the presence of risk factors for cancer recurrence.
These findings from the Spanish Breast Cancer Research Group (GEICAM 9805) trial published in the December 2010, New England Journal of Medicine, expand upon the results of the randomized BCIRG 001 trial, which show that TAC is effective both in patients with node-positive and in those with high-risk, node-negative early-stage breast cancer.
In their paper, researchers stressed, "Most taxane trials have focused on patients with axillary-lymph-node-positive breast cancer, although a small number of trials have involved both patients with node-positive disease and those with node-negative disease." They further emphasized, "Although some current estimates show that a majority of patients with operable breast cancer have node-negative disease at diagnosis, there is little guidance about taxane use in patients with node-negative disease."
Rates of grade 3 and 4 adverse events (according to the National Cancer Institute's Common Toxicity Criteria) occurred in 28.2% of patients treated with TAC and 17.0% of those treated with FAC (P<.001), with serious events occurring at rates of 22.4% and 4.2%. Neutropenia and leukopenia (P<.001 for both) were the most significant adverse events caused by TAC. The researchers underscored, however, "The acute toxic effects associated with TAC are manageable when treatment is combined with primary G-CSF prophylaxis."
Also of note, overall survival rates (TAC, 95.2%; FAC, 93.5%) were not significantly different between TAC- and FAC-treated patients (HR=0.76; 95% CI, 0.45–1.26); although, the number of deaths during trial follow-up was small (n=60).
"Because of the limited number of deaths, survival data are still immature," the authors noted. "The small number of deaths occurring at the time of analysis indicates that a longer follow-up period will be needed to assess survival among patients with node-negative breast cancer as compared with those who have node-positive disease."
The prior BCIRG 001 trial in women with node-positive breast cancer showed TAC reduced overall mortality by a statistically significant 30% compared to FAC (P=.008).
SOURCE
Martín M, Seguí MA, Antón A; GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative breast cancer. New Engl J Med. 2010;363(23):2200–2210.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More